A Multicenter, Open-Label Long Term Safety Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in a Prior AR101 Study (ARC008)
Study ID: STU 092017-039
Summary
1)To describe the long-term safety and tolerability of AR101 using a CODIT(TM) regimen administered to peanut-allergic children and adults 2)To assess the level of desensitization achievable through extended maintenance dosing of AR101 3)To characterize the